Ubs Group Ag Crispr Therapeutics Ag Transaction History
Ubs Group Ag
- $555 Billion
- Q2 2025
A detailed history of Ubs Group Ag transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Ubs Group Ag holds 2,843,577 shares of CRSP stock, worth $164 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,843,577
Previous 2,071,892
37.25%
Holding current value
$164 Million
Previous $70.5 Million
96.17%
% of portfolio
0.02%
Previous 0.01%
Shares
34 transactions
Others Institutions Holding CRSP
# of Institutions
531Shares Held
68.7MCall Options Held
3.67MPut Options Held
2.25M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$589 Million4.09% of portfolio
-
Capital International Investors Los Angeles, CA5.59MShares$324 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.68MShares$213 Million0.11% of portfolio
-
State Street Corp Boston, MA3.27MShares$189 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$161 Million0.0% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.51B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....